Eleftheria Hatzimichael, MD, PhD

Associate Professor of Haematology

Faculty of Medicine, School of Health Sciences, University of Ioannina

Short CV

Eleftheria Hatzimichael, MD, PhD (born 1975) is a Haematologist, with a strong background and research activities in epigenetics and translational research. and currently an Associate Professor of Haematology, in the Faculty of Medicine, School of Health Sciences, University of Ioannina Greece. She graduated from the School of Medicine, University of Ioannina in 1998 and was trained in Haematology at St. Bartholomew’s Hospital, Barts and the London Trust, London, UK and the University Hospital of Ioannina, Ioannina, Greece. For her achievements on 2011, she was awarded a prestigious early-carrier one-year fellowship from the Hellenic Society of Haematology Foundation to work with Dr Isidore Rigoutsos as a Visiting Scientist at the Computational Medicine Centre, Jefferson Medical College, Thomas Jefferson University, US, in the field of the non-coding human genome by computational and experimental approaches. She has also received the prestigious Clinical Research Training in Haematology award 2016-2017 by the European Haematology Association, 9-month-long unique training and mentoring experience focused on clinical research in Europe, with a global scope. 

She is the PI of more than 30 Phase II-IV clinical trials and has served as a subinvestigator in more than 25 phase I-III clinical trials and as a reviewer for more than 27 journals. She is a member of the Associate Editorial Board of the American Journal of Blood Research and member of the Editorial Board of Diseases (section Oncology), Associate Editor in Frontiers in Medicine (section Hematology) and a member of the Hellenic Society of Haematology, the Greek Myeloma Study Group (GMSG), The Greek (Hellenic) MDS Group, the American Society of Hematology, the European Cancer Research Association, and the European Haematology Association. She is also the Secretary of the Steering Committee of the Scientific Department of Myelodysplastic Syndromes and Marrow Failure of the Hellenic Society of Hematology, 2022-2023, 2024-2025, and a Member of the Board of Directors of the Hellenic Society of Hematology, 2022-2024.

She has more than 130 papers in peer-reviewed journals with an h-index of 32 (source Scopus). 

Medical education

1992-1998 Medical School of Ioannina, University of Ioannina, Ioannina, Greece

Jul 1998 Medical License  9894/ 27-7-1998                                           

Dec 2008 PhD, Medical School of Ioannina, University of Ioannina, Greece

Title of thesis: “Study of the expression and clinical significance of cyclins and the methylation status of cyclin inhibitors in hematological malignancies”

Education relevant to clinical research

Publications

 

-----elected Associate Professor of Haematology

 

 

-----elected Assistant Professor of Haematology

 

*equal contribution

*equal contribution


Author Metrics


Citations

3,628

Citations by 3,343 documents


h-index 32


Clinical Trials

As Primary Investigator

  1.  Phase 3 Randomized, Controlled Study of Blinatumomab Alternating with Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in (Golden Gate Study)
  2. A Phase 2 study of Isatuximab in combination with Pomalidomide and Dexamethasone in MM patients who received one prior line of therapy containing Lenalidomide and a Proteasome Inhibitor, EAE-115, Sponsor Hellenic Society of Haematology
  3. A Phase 2 Study of Isatuximab in combination with Bortezomib, Cyclophosphamide, and Dexamethasone, followed by Isatuximab and Lenalidomide maintenance in Newly Diagnosed Patients with Multiple Myeloma and severe Renal Impairment, EAE-116, Sponsor Hellenic Society of Haematology
  4. An open-label, 3-arm, multicenter, randomized phase 3 study to evaluate the efficacy and safety of Elranatamab (pf-06863135) monotherapy and Elranatamab + Daratumumab versus Daratumumab + Pomalidomide + Dexamethasone in participants with Relapsed/Refractory Multiple Myeloma who have received at least 1 prior line of therapy including Lenalidomide and a proteasome inhibitor, MagnetisMM 05 / C1071005, Sponsor Pfizer
  5. An open-label, 2-arm, multicenter, randomized phase 3 study to evaluate the efficacy and safety of elranatamab (pf-06863135) + daratumumab + lenalidomide versus daratumumab + lenalidomide + dexamethasone in transplant-ineligible participants with newly-diagnosed multiple myeloma, C1071006, MagnetisMM-6, Sponsor Amgen
  6. A randomized, 2-arm, phase 3 study of Elranatamab (PF-06863135) versus Lenalidomide in patients with newly diagnosed Multiple Myeloma who are minimal residual disease-positive after undergoing autologous stem-cell transplantation,  MagnetisMM 07 / C1071007, Sponsor Pfizer
  7. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Navtemadlin Plus Ruxolitinib Versus Placebo Plus Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) Following a Suboptimal Response to Ruxolitinib” (BOREAS-2)
  8. A phase 1/3 study to evaluate the efficacy and safety of selinexor, a selective inhibitor of nuclear export, in combination with ruxolitinib in treatment-naïve patients with myelofibrosis, XPORT-MF-034, Sponsor Karyopharm
  9. A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT-232 in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment, Sponsor Kartos Therapeuticals
  10. A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients (CPI 0610-04, MANIFEST-2)
  11. Double-Blind, Randomized, Placebo-Controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia, Sponsor Octapharma
  12. A Randomized, Controlled, Open-label, Multicenter, Inferentially Seamless Phase 2/Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Combination with Rituximab Versus Physician’s Choice of Lenalidomide Plus Rituximab or Bortezomib Plus Rituximab in Participants with Relapsed or Refractory Mantle Cell Lymphoma who are BTK inhibitor-naïve, Sponsor: Janssen Pharmaceuticals
  13. A Multi-Country, Real-World Study to Explore Treatment Patterns, Effectiveness and Healthcare Resource Utilization for Patients Diagnosed with Myelofibrosis through Chart Review, the METER study, Sponsor Abbvie
  14. 16. Προοπτική μη παρεμβατική μελέτη για την περιγραφή της αποτελεσματικότητας και της ασφάλειας του ως θεραπεία πρώτης γραμμής σε ασθενείς με οξεία μυελοειδή λευχαιμία (ΟΜΛ) οι οποίοι δεν είναι κατάλληλοι για εντατική χημειοθεραπεία στη συνήθη κλινική πρακτική στην Ελλάδα», Μελέτη SURVIVE, Sponsor: AbbVie
  15. A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator’s Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy
  16. Μια πολυκεντρική, ανοιχτής ετικέτας, τυχαιοποιημένη μελέτη Φάσης III για την αξιολόγηση της αποτελεσματικότητας και της ασφάλειας του Belantamab Mafodotin σε συνδυασμό με πομαλιδομίδη και δεξαμεθαζόνη (B-Pd) έναντι του συνδυασμού με πομαλιδομίδη, βορτεζομίμπη και δεξαμεθαζόνη (PVd) σε συμμετέχοντες με υποτροπιάζον/ανθεκτικό πολλαπλό μυέλωμα (DREAMM 8), Sponsor GlaxoSmithKline
  17. An Open-label, Phase 2 Study Treating Subjects with First or Second Relapse of MM with Carfilzomib, Pomalidomide, and Dexamethasone (KPd), Sponsor Amgen
  18. Μελέτη MiraCLLe: Μια Eπιδημιολογική, Προοπτική μελέτη κοόρτης, διετούς διάρκειας για να Καταγράψει την Πραγματική Στρατηγική Αντιμετώπισης Πρώτης και Δεύτερης Γραμμής θεραπεία, στην Καθ’ Ημέρα Κλινική Πράξη, Αποτελέσματα Θεραπείας, Ποιότητα Ζωής και Χρήση Πόρων σε Ασθενείς με Χρόνια Λεμφοκυτταρική Λευχαιμία στην Ελλάδα, Sponsor Astra Zeneca
  19. A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of IMP in Adult Study Participants with Persistent or Chronic Primary Immune Thrombocytopenia (ITP), Sponsor: UCB Biopharma SRL
  20. Study M20-638: A Phase 3, Multicenter, Randomized, Open-Label Trial of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to Rituximab and Lenalidomide (R2) alone in Subjects with Relapsed or Refractory Follicular Lymphoma, Sponsor: AbbVie
  21. Study M20-621: A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma Version Number: 1.0, Sponsor: AbbVie
  22. PCYC-1143-CA: A Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma, Sponsor: Pharmacyclics
  23. P19-568/Concrete: Κλινικές Εκβάσεις ασθενών με υποτροπιάζουσα/ανθεκτική Χρόνια Λεμφοκυτταρική Λευχαιμία (Υ/Α ΧΛΛ) οι οποίοι υποβάλλονται σε θεραπεία με Venetoclax σε συνθήκες καθημερινής κλινικής πρακτικής στην Ελλάδα, (Clinical outcomes of relapse/refractory Chronic Lymphocytic Leukemia (R/R CLL) patients treated with venetoclax in routine clinical settings in Greece) Sponsor: AbbVie Φαρμακευτική ΑΕ
  24. ΑSPER-III-19-1: Μία φάσης 3, διπλή-τυφλή, πολυκεντρική, τυχαιοποιημένη, ελεγχόμενη με εικονικό φάρμακο μελέτη για την αξιολόγηση της αποτελεσματικότητας, της ασφάλειας και της ανεκτικότητας της εισπνεόμενης Ιτρακοναζόλης  σε μορφή ξηράς κόνεως για την πρόληψη της διηθητικής μυκητιασικής  λοίμωξης σε ασθενείς με Οξεία Λευχαιμία και Ουδετεροπενία, (A phase 3, double-blind, multicentric, randomized, placebo-controlled study to assess the efficacy, safety and tolerability of Itraconazole dry powder for inhalation for the prevention of invasive mould disease in patients with Acute Leukaemia and Neutropaenia) Sponsor: Laboratoires SMB S.A 
  25.  Αναδρομική ανάλυση κλινικών εκβάσεων ασθενών με υποτροπιάζουσα/ανθεκτική Χρόνια Λεμφοκυτταρική Λευχαιμία (Υ/Α ΧΛΛ) που υποβλήθηκαν σε θεραπεία με venetoclax: Αναδρομική ανάλυση από την Ελλάδα, Sponsor: AbbVie Φαρμακευτική ΑΕ
  26. Α phase III, randomized, open­label, active-controlled, multicenter study evaluating the efficacy and safety of Crovalimab versus Eculizumab in adult and adolescent patients with paroxysmal nocturnal hemoglobinuria not previously treated with complement inhibitors, Sponsor Hoffmann-La Roche
  27. An Open-label, Phase 2 Study Treating Subjects with First or Second Relapse of Multiple Myeloma with Carfilzomib, Pomalidomide, and Dexamethasone (KPd), Sponsor: Amgen
  28. Τυχαιοποιημένη, διπλά-τυφλή, ελεγχόμενη με εικονικό φάρμακο πολυκεντρική μελέτη φάσης ΙΙΙ της αζακιτιδίνης με ή χωρίς MBG453 για τη θεραπεία ασθενών με ενδιάμεσου, υψηλού ή πολύ υψηλού κινδύνου μυελοδυσπλαστικό σύνδρομο (ΜΔΣ) σύμφωνα με τα κριτήρια IPSS-R, ή με χρόνια μυελομονοκυτταρική λευχαιμία-2 (CMML-2), Sponsor: Novartis